- Conditions
- Postmenopausal Women With Osteoporosis
- Interventions
- Romosozumab, Alendronate, Placebo to Romosozumab, Placebo to Alendronate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 4,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–11
of 11
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Osteoporosis in Men
- Interventions
- Romosozumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Male only
- Enrollment
- 245 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Bethesda, Maryland • Albuquerque, New Mexico
- Conditions
- Fracture Healing
- Interventions
- Romosozumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Orange, California • Aurora, Colorado + 11 more
- Conditions
- FHA (Functional Hypothalamic Amenorrhea)
- Interventions
- Romosozumab, Placebo, Zoledronic acid
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 14 Years to 30 Years · Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlottesville, Virginia
- Conditions
- Bone Density, Low, Bone Loss, Anorexia Nervosa, Eating Disorders
- Interventions
- Romosozumab Prefilled Syringe, Placebo, Zoledronic acid 5 mg
- Drug
- Lead sponsor
- Karen Klahr Miller, MD
- Other
- Eligibility
- 20 Years to 60 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Osteoporosis, Post-menopausal
- Interventions
- Romosozumab, Alendronate (Fosamax), Placebo Romosozumab, Placebo Alendronate
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 294 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Gainesville, Georgia • Bethesda, Maryland
- Conditions
- Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI
- Interventions
- Romosozumab, Denosumab, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 2
- States / cities
- West Orange, New Jersey • The Bronx, New York
- Conditions
- Osteoporosis, Osteoporosis, Postmenopausal, Osteoporosis Fracture
- Interventions
- Romosozumab, Placebo, Zoledronic acid, Calcium and Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Susan L. Greenspan
- Other
- Eligibility
- 65 Years and older · Female only
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Romosozumab, Placebo, Denosumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 7,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Laguna Hills, California • Los Angeles, California + 22 more
- Conditions
- Fracture Healing
- Interventions
- Placebo, Romosozumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 55 Years to 95 Years
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Pomona, California • Aurora, Colorado + 9 more